Amneal Pharmaceuticals (NASDAQ:AMRX) Upgraded by Wall Street Zen to “Strong-Buy” Rating

Amneal Pharmaceuticals (NASDAQ:AMRX) was upgraded by equities researchers at Wall Street Zen from a “buy” rating to a “strong-buy” rating in a report released on Sunday.

Other equities analysts have also recently issued reports about the company. UBS Group assumed coverage on Amneal Pharmaceuticals in a report on Friday, April 17th. They issued a “buy” rating and a $19.00 price target for the company. Zacks Research cut Amneal Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Monday, April 6th. Weiss Ratings downgraded shares of Amneal Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Tuesday, May 26th. Finally, Barclays upped their target price on shares of Amneal Pharmaceuticals from $15.00 to $16.00 and gave the company an “overweight” rating in a report on Wednesday, May 20th. Five equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat.com, Amneal Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $15.80.

Amneal Pharmaceuticals Stock Down 0.1%

Shares of AMRX traded down $0.01 during mid-day trading on Friday, reaching $17.01. 1,733,359 shares of the company’s stock were exchanged, compared to its average volume of 2,108,096. Amneal Pharmaceuticals has a 52-week low of $7.66 and a 52-week high of $17.86. The company has a market cap of $5.43 billion, a price-to-earnings ratio of 44.76 and a beta of 1.26. The company has a 50-day simple moving average of $14.64 and a two-hundred day simple moving average of $13.73.

Amneal Pharmaceuticals (NASDAQ:AMRX) last posted its earnings results on Thursday, May 7th. The company reported $0.27 earnings per share (EPS) for the quarter. The firm had revenue of $722.52 million for the quarter. Amneal Pharmaceuticals had a negative return on equity of 313.96% and a net margin of 4.01%. As a group, equities research analysts predict that Amneal Pharmaceuticals will post 0.92 EPS for the current fiscal year.

Insider Activity

In other news, Director Deborah M. Autor sold 34,819 shares of Amneal Pharmaceuticals stock in a transaction on Monday, May 11th. The stock was sold at an average price of $12.94, for a total value of $450,557.86. Following the completion of the sale, the director owned 93,660 shares of the company’s stock, valued at $1,211,960.40. The trade was a 27.10% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 17.30% of the stock is owned by company insiders.

Institutional Trading of Amneal Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of Amneal Pharmaceuticals by 4.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 94,638 shares of the company’s stock valued at $793,000 after acquiring an additional 4,178 shares during the last quarter. Millennium Management LLC boosted its position in shares of Amneal Pharmaceuticals by 32.6% in the first quarter. Millennium Management LLC now owns 2,087,398 shares of the company’s stock worth $17,492,000 after acquiring an additional 512,842 shares during the last quarter. Dynamic Technology Lab Private Ltd purchased a new stake in Amneal Pharmaceuticals in the first quarter valued at approximately $244,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in Amneal Pharmaceuticals by 5.2% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 334,956 shares of the company’s stock worth $2,807,000 after purchasing an additional 16,536 shares during the last quarter. Finally, Creative Planning increased its position in Amneal Pharmaceuticals by 61.9% during the second quarter. Creative Planning now owns 23,896 shares of the company’s stock worth $193,000 after purchasing an additional 9,136 shares during the last quarter. 31.82% of the stock is owned by institutional investors and hedge funds.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.